OncoTelic's Convertible Note Round

OncoTelic raised a round of funding on February 09, 2016.

Oncotelic's lead therapeutic platform is OT-101 (Trabedersen). Oncotelic intends to conduct registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma.…

Articles about OncoTelic's Convertible Note Round: